Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions - Wikidata - wikimedia - TriplyDB

Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions

Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions

http://www.wikidata.org/entity/Q28365296

about

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal Integrated therapy for HIV and cryptococcosis Increased permeability of blood-brain barrier is mediated by serine protease during Cryptococcus meningitis A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi Chemical Inhibitors of Non-Homologous End Joining Increase Targeted Construct Integration in Cryptococcus neoformans Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells Siderophores; iron scavengers: the novel & promising targets for pathogen specific antifungal therapy.Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania Neuromeningeal cryptococcosis in sub-Saharan Africa: Killer disease with sparse data Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi Cryptococcal meningitis: epidemiology and therapeutic options.Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine Molecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults.Antifungal drug discovery through the study of invertebrate model hosts.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Predictors of bacterial meningitis in resource-limited contexts: an Angolan case.Resistance to antifungals that target CYP51.Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.An update on Cryptococcus among HIV-infected patients.Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.Massive cerebral edema resulting in brain death as a complication of Cryptococcus neoformans meningitis.Combination Versus Monotherapy for the Treatment of HIV Associated Cryptococcal Meningitis Comparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: a network meta-analysis.The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis.Antibiotic treatment for bacterial meningitis in children in developing countries.Management of cryptococcal meningitis in a district hospital in KwaZulu-Natal: a clinical audit The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier.Central Nervous System Cryptococcosis among a Cohort of HIV Infected Patients from a University Hospital of North India.Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.A Retrospective Cohort Study of Lesion Distribution of HIV-1 Infection Patients With Cryptococcal Meningoencephalitis on MRI: Correlation With Immunity and Immune Reconstitution.The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya.HIV and co-infections.Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy.Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings.Epidemiology and management of cryptococcal meningitis: developments and challenges.New Insights into HIV/AIDS-Associated Cryptococcosis.The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya Asymptomatic cryptococcemia in resource-limited settings.

P2860

Q24678763-EC623E27-9A0E-4B01-8610-ACC736AB39D9 Q27012487-3F902CD9-B120-4F7D-BACC-A43D712B4459 Q28077707-8C8DCF56-81AD-44F3-85D8-898483C29F9F Q28305427-2C50D795-60C9-4CAE-9D9B-914839C46E0A Q28534417-ACC8B1C2-61FD-41EA-BBAA-6E3E7C74AB03 Q28554238-7DE23DD1-088C-4281-9A8B-5BC814140B1E Q28730545-5DF0CC04-E9D3-4788-A921-AD18D8A76D75 Q30243906-677AEADF-B518-4494-90C8-A5780ACA87F4 Q30444984-63B40F42-B265-4A53-A8F0-2023C67A95AA Q30934853-388D559F-3297-4D8A-8875-8FB103DF74E0 Q33588561-88084F9A-F9A5-4D21-8A11-D6103DD18846 Q33633343-6F6B9D12-F9E9-4488-9BFC-C21276241EA3 Q33676182-407522E2-4978-4DB3-8570-18F5C72AFE4D Q33678132-6C400E16-8F4E-404B-9A7F-3064D0BC273D Q34002069-5EEDA090-AEB3-4D76-9237-D215E1087CD2 Q34020746-1425F109-43CF-4C48-A5B2-1F693107FBD0 Q34047089-EDCE9E86-A964-4FB4-B3B0-FF37470BB636 Q34276700-BD6A0396-A84A-48C9-8883-6615A413975A Q34459194-602D6377-5BFF-4C1F-8A16-E728A97B7F6D Q34625655-0202C301-5D09-4FD1-9FF1-7FCE8C7191D2 Q34874626-228D2402-DAAA-4BBF-8C67-E21114C4C058 Q35054798-C8B2FF68-17BC-4588-AB12-875A6CFC9DAC Q35230534-A909F010-6051-4329-9605-4A40EB548882 Q35628245-5FC01791-36C6-4032-AA32-D3743B524AC4 Q35635476-B707CE10-A0FD-438B-A885-320F326495EE Q35635850-42E7F23C-BDD6-47AC-9C6E-E8BD170F2DAA Q35853546-6AEB44CA-5F6F-49D9-801A-DCC63C4EFAF2 Q36012849-EEDBDA66-A609-4608-BBB8-C9382276A21C Q36236518-31F44688-FF5D-4514-A5BE-D2902BB0A4D6 Q36318103-7FB628CF-EC46-4F86-88DF-F49C24C42D4B Q36489747-A555E300-B1BC-4BD0-900A-3E6FBD9C802E Q36580897-36EA567B-E082-4997-8F9F-7D68A43DD372 Q36700649-F8D2979A-4091-403D-8F95-16C0470A898D Q36970184-A8A0149D-CB5B-4C47-B804-4321F5C92BE6 Q36996124-2B4FF541-467C-4CD9-B3E2-7E9278EE6403 Q37043583-F8E0BD2B-09A4-432A-AD88-B4BA3E1C087D Q37098995-CA3180BF-585E-4405-A4CD-540C69A5CC52 Q37156556-E1B34F0D-DEA3-4120-8ADF-C0584327F163 Q37259604-CADF691C-1B7E-481F-BAC5-EFCCA49D7565 Q37259640-AFA72662-1D47-4909-9E0C-5324DF45599B

P2860

Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions

http://www.wikidata.org/entity/Q28365296

description

2001 nî lūn-bûn

@nan

2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

name

Clinical presentation, natural ...... treated under local conditions

@ast

Clinical presentation, natural ...... treated under local conditions

@en

Clinical presentation, natural ...... treated under local conditions

@nl

type

label

Clinical presentation, natural ...... treated under local conditions

@ast

Clinical presentation, natural ...... treated under local conditions

@en

Clinical presentation, natural ...... treated under local conditions

@nl

prefLabel

Clinical presentation, natural ...... treated under local conditions

@ast

Clinical presentation, natural ...... treated under local conditions

@en

Clinical presentation, natural ...... treated under local conditions

@nl

P1433

Q28365296-06A99C0E-D6DA-4F00-8BFB-35DA09E47BEB

P1476

Q28365296-E9871DDE-1703-4B0B-9E25-BD132B18A411

P2093

Q28365296-01411D80-503B-459D-854E-7ABDEA26E881

Q28365296-4188CCEE-3CBA-4E94-AA2F-600B9251D364

Q28365296-E5F19FE6-DC5C-4C47-8D5F-61A91C77C800

Q28365296-E68945CA-67C4-4ACB-9DA0-4E0F299E4A8A

Q28365296-E743106E-5A9D-498F-9292-724960B7E4DA

P2860

Q28365296-18809C5B-0160-4F50-A863-F1FBD9455DF1

Q28365296-30968679-FA73-4243-AE71-751B267B1F38

Q28365296-5A820AB5-96F1-4C89-9CC1-02BD2C62571A

Q28365296-5BB0233F-6EB3-4550-B4B1-C7BFC8045D5D

Q28365296-72AE8A1F-B27A-4738-9935-FB5F40E3EF77

Q28365296-743C430B-B13D-4C5C-8793-2E7E06120218

Q28365296-9AFC3E06-C9E1-4AEF-A415-5CA88B685F18

Q28365296-9FBEEF20-635C-4CF2-B805-B0AA85F8F05A

Q28365296-B5BBC1C2-2F7F-4401-A918-AE9F714BBA1E

Q28365296-C0DE0F6E-01E0-4429-A4B3-D9AFEDE9C182

P304

Q28365296-A8C2B20F-C460-4439-92AC-682BE051D32B

P31

Q28365296-93BD382D-02A7-4ECB-8936-3A9AC6FE3343

P3181

Q28365296-17EC6ECE-A497-46FF-A7EF-FBEB12E98A9F

P356

Q28365296-6A2FA339-AC87-4449-AD0C-6EDCABABD66B

P407

Q28365296-F46B7E9F-9763-4772-A44A-62525E157333

P433

Q28365296-B5935660-5083-4D80-A9A3-1EF56858A9C9

P478

Q28365296-DFA4EB34-8C4A-4958-BAE3-A081A3B9C549

P50

Q28365296-A15AD9E0-4F31-4705-B67B-D45DB8BA912E

Q28365296-A4E6C66A-FBD3-4DA4-8A3B-BEE9CBF3F434

P577

Q28365296-1A4B3E7E-F3A8-4E49-A810-8B8778D2D00B

P5875

Q28365296-D803698F-0A07-4DDA-A090-EBB2D2FCCA87

P698

Q28365296-E3F5D674-A8FB-4948-A1C7-9459D910FF7F

P921

Q28365296-4F3C9775-36FB-44E0-B008-6790E55A7023

Q28365296-53ED2F85-F47C-49ED-B61A-3EFC70CEE6C3

Q28365296-59165CCF-863F-41B0-BB48-F5D791117781

Q28365296-E27A4E0A-8F7C-49D5-BA8E-3588B5626F65

P932

Q28365296-9F2B2066-3834-4A68-B2B9-B85C4F7B455C

P3181

P356

P1433

Postgraduate Medical Journal

P1476

Clinical presentation, natural ...... treated under local conditions

@en

P2093

C Chintu

http://www.w3.org/2001/XMLSchema#string

J Mwansa

http://www.w3.org/2001/XMLSchema#string

J Pobee

http://www.w3.org/2001/XMLSchema#string

P Mwaba

http://www.w3.org/2001/XMLSchema#string

S Portsmouth

http://www.w3.org/2001/XMLSchema#string

P2860

Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.

The HIV epidemic in Zambia: socio-demographic prevalence patterns and indications of trends among childbearing women.

Cryptococcal meningitis in Lilongwe and Blantyre, Malawi.

Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients.

Recent advances in the management of cryptococcal meningitis in patients with AIDS.

Cryptococcal disease: implications of recent clinical trials on treatment and management.

High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group.

High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

P304

769-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3468693

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/PMJ.77.914.769

http://www.w3.org/2001/XMLSchema#string

P407

P433

914

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P50

Matthew Scarborough

Alimuddin Zumla

P577

2001-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277524636

http://www.w3.org/2001/XMLSchema#string

P698

11723315

http://www.w3.org/2001/XMLSchema#string

P921

P932

1742198

http://www.w3.org/2001/XMLSchema#string